Biosketch

Matthieu Mahévas is a physician-researcher affiliated with the French reference center for immune thrombocytopenia at Henri-Mondor Hospital, known as CERECAI. He completed his PhD within the research laboratory of Claude-Agnès Reynaud and Jean-Claude Weill at INEM. During this period, his research demonstrated the impact of B cell-depletion therapy in facilitating the emergence of long-lived pathogenic plasma cells within the spleen.
In 2014, he was appointed MCU-PH, and in 2019, he achieved the position of PU-PH at the Faculté de Médecine de l’Université Paris-Est Créteil. His remarkable work earned him an ATIP/Avenir grant in 2022. Since 2023, he has held the position of leader of the "Auto-immune and immune B cells (AI2B)" group at INEM. In this role, he continues to pursue his early clinical and scientific research interests, centered on unraveling the cellular and molecular mechanisms underlying autoimmune diseases and developing innovative therapies. He has been actively involved in numerous clinical trials, including RITUX-PLUS, RITUX-PLUS2, IVIORDEX, and STOPAGO.
More recently, Matthieu Mahévas and his group have harnessed their unique expertise to explore human B cells at the single-cell level, contributing seminal work on the maturation of memory B cells following SARS-CoV-2 infection and mRNA vaccination. In recognition of his significant contributions to the field, he was elected as a fellow of the Henri Kunkel Society in 2021.